Novel 4-Bromobenzyl-1H-1,2,3-Triazole Scaffold for Multi-target Enzyme Inhibition in Helicobacter Gastric Injury via Experimental and Computational Approaches


Akkar M. E., Ortaakarsu A. B., Boğa Ö. B., KURBANOĞLU E. B., ALTUNDAŞ A.

Journal of Pharmaceutical Innovation, cilt.21, sa.1, 2026 (SCI-Expanded, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 1
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1007/s12247-025-10298-9
  • Dergi Adı: Journal of Pharmaceutical Innovation
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, INSPEC
  • Anahtar Kelimeler: 1,2,3-triazole, Gastric ulcer, Helicobacter pylori, Molecular dynamics, Multi-target enzyme inhibition, Urease inhibition
  • Gazi Üniversitesi Adresli: Evet

Özet

Regioselective elaboration of a 4-bromobenzyl-1H-1,2,3-triazole scaffold was achieved through a concise, metal-free sequence that preserves the C-4 carboxylate as a metal-coordinating handle while diversifying the C-5 position. Thermal azide–alkyne cycloaddition between 1-(azidomethyl)-4-bromobenzene and dimethyl but-2-ynedioate furnished the 4,5-diester core, followed by LTBA-mediated, chemoselective reduction of the C-5 ester to an aldehyde at − 10 °C in THF. Modular condensation of the aldehyde delivered three derivatives—Schiff base (a2), hydrazone (a3), and benzimidazole (a1)—in 95–98% yields, with structures confirmed by NMR and HRMS. The regioselective design maximized metal coordination (Ni²+, Zn²+, Fe³+) and produced multi-target inhibition against urease, collagenase, and 15-LOX; the imine derivative a2 was most potent (IC50: 7.21 µM, 27.36 µM, 2.76 µM, respectively), consistent with docking, MD, and MM/GBSA analyses. This synthesis-first strategy establishes a privileged, polypharmacological platform for gastric-injury targets.